Clinical & Experimental Metastasis最新文献_第9页

Correction to: PITX1 suppresses osteosarcoma metastasis through exosomal LINC00662-mediated M2 macrophage polarization 更正为PITX1 通过外泌体 LINC00662 介导的 M2 巨噬细胞极化抑制骨肉瘤转移

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-08 DOI: 10.1007/s10585-023-10247-1

Ying Zhang, Yelong Chen, Chuangzhen Chen, Huancheng Guo, Chunbin Zhou, Hu Wang, Zhaoyong Liu

引用次数: 0

Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance? 黑色素瘤的管理：我们能否利用基因表达谱来帮助指导治疗和监控？

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-08 DOI: 10.1007/s10585-023-10241-7

Jonathan S. Zager, David M. Hyams

{"title":"Management of melanoma: can we use gene expression profiling to help guide treatment and surveillance?","authors":"Jonathan S. Zager, David M. Hyams","doi":"10.1007/s10585-023-10241-7","DOIUrl":"https://doi.org/10.1007/s10585-023-10241-7","url":null,"abstract":"Although the incidence of cutaneous melanoma (CM) has been increasing annually, the mortality rate has been decreasing, likely due to better prevention, earlier detection, improved surveillance, and the development of new therapies. Current clinical management guidelines by the National Comprehensive Cancer Network (NCCN) are based on patient risk assignment using staging criteria established by the American Joint Committee on Cancer (AJCC). However, some patients with localized disease (stage I–II), generally considered to have a good prognosis, will develop metastatic disease and die, whereas some patients with later stage disease (stage III–IV) will be cured by surgery, adjuvant therapy, and/or systemic therapy. These results emphasize the importance of identifying patients whose risk may be over or underestimated with standard staging. Gene expression profile (GEP) tests are noninvasive molecular tests that assess the expression levels of a panel of validated genes, providing information about tumor prognosis, including the risk of recurrence, metastasis, and cancer-specific death. GEP tests can provide prognostic information beyond standard staging that may aid clinicians and patients in treatment and surveillance management decisions. This review describes how combining clinicopathologic staging with a robust assessment of tumor biology may provide information that will allow more refined intervention and long-term management.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138556759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases – data from a tertiary care center 肺大细胞神经内分泌癌脑转移患者的临床特征、治疗和预后--来自一家三级医疗中心的数据

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-08 DOI: 10.1007/s10585-023-10250-6

Petar Popov, Ariane Steindl, Ladislaia Wolff, Elisabeth S. Bergen, Franziska Eckert, Josa M Frischer, Georg Widhalm, Thorsten Fuereder, Markus Raderer, Anna S. Berghoff, Matthias Preusser, Barbara Kiesewetter

{"title":"Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases – data from a tertiary care center","authors":"Petar Popov, Ariane Steindl, Ladislaia Wolff, Elisabeth S. Bergen, Franziska Eckert, Josa M Frischer, Georg Widhalm, Thorsten Fuereder, Markus Raderer, Anna S. Berghoff, Matthias Preusser, Barbara Kiesewetter","doi":"10.1007/s10585-023-10250-6","DOIUrl":"https://doi.org/10.1007/s10585-023-10250-6","url":null,"abstract":"Large cell neuroendocrine carcinoma (LCNEC) of the lung is an aggressive malignancy, with brain metastases (BM) occurring in approximately 20% of cases. There are currently no therapy guidelines for this population as only few data on the management of LCNEC and BM have been published. For this retrospective single center study, patients with LCNEC and BM were identified from the Vienna Brain Metastasis Registry. Data on clinicopathological features, BM-specific characteristics, treatment, and outcome were extracted. In total, 52/6083 (0.09%) patients in the dataset had a diagnosis of LCNEC and radiologically verified BM. Median age at diagnosis of LCNEC and BM was 59.1 and 60.1 years, respectively. Twenty-seven (51.9%) presented with single BM, while 12 (23%) exhibited > 3 BM initially. Neurologic symptoms due to BM were present in n = 40 (76.9%), encompassing neurologic deficits (n = 24), increased intracranial pressure (n = 18), and seizures (n = 6). Initial treatment of BM was resection (n = 13), whole brain radiation therapy (n = 19), and/or stereotactic radiosurgery (n = 25). Median overall survival (mOS) from LCNEC diagnosis was 16 months, and mOS after BM diagnosis was 7 months. Patients with synchronous BM had reduced mOS from LCNEC diagnosis versus patients with metachronous BM (11 versus 27 months, p = 0.003). Median OS after BM diagnosis did not differ between LCNEC patients and a control group of small cell lung cancer patients with BM (7 versus 6 months, p = 0.17). Patients with LCNEC and BM have a poor prognosis, particularly when synchronous BM are present. Prospective trials are required to define optimal therapeutic algorithms.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138555242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics 通过单细胞和空间转录组学剖析肿瘤微环境对免疫检查点抑制剂的反应

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-08 DOI: 10.1007/s10585-023-10246-2

Wendi Liu, Anusha Puri, Doris Fu, Lee Chen, Cassia Wang, Manolis Kellis, Jiekun Yang

{"title":"Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics","authors":"Wendi Liu, Anusha Puri, Doris Fu, Lee Chen, Cassia Wang, Manolis Kellis, Jiekun Yang","doi":"10.1007/s10585-023-10246-2","DOIUrl":"https://doi.org/10.1007/s10585-023-10246-2","url":null,"abstract":"Cancer is a disease that undergoes selective pressure to evolve during its progression, becoming increasingly heterogeneous. Tumoral heterogeneity can dictate therapeutic response. Transcriptomics can be used to uncover complexities in cancer and reveal phenotypic heterogeneity that affects disease response. This is especially pertinent in the immune microenvironment, which contains diverse populations of immune cells, and whose dynamic properties influence disease response. The recent development of immunotherapies has revolutionized cancer therapy, with response rates of up to 50% within certain cancers. However, despite advances in immune checkpoint blockade specifically, there remains a significant population of non-responders to these treatments. Transcriptomics can be used to profile immune and other cell populations following immune-checkpoint inhibitor (ICI) treatment, generate predictive biomarkers of resistance or response, assess immune effector function, and identify potential immune checkpoints. Single-cell RNA sequencing has offered insight into mRNA expression within the complex and heterogeneous tumor microenvironment at single-cell resolution. Spatial transcriptomics has enabled measurement of mRNA expression while adding locational context. Here, we review single-cell sequencing and spatial transcriptomic research investigating ICI response within a variety of cancer microenvironments.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138555343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High sensitivity flow cytometry immunophenotyping increases the diagnostic yield of malignant pleural effusions. 高灵敏度的流式细胞术免疫表型可提高恶性胸腔积液的诊断率。

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-01 Epub Date: 2023-10-09 DOI: 10.1007/s10585-023-10236-4

Dolores Subirá, Fabiola Barriopedro, Jesús Fernández, Ruth Martínez, Luis Chara, Jorge Castelao, Eugenia García

{"title":"High sensitivity flow cytometry immunophenotyping increases the diagnostic yield of malignant pleural effusions.","authors":"Dolores Subirá, Fabiola Barriopedro, Jesús Fernández, Ruth Martínez, Luis Chara, Jorge Castelao, Eugenia García","doi":"10.1007/s10585-023-10236-4","DOIUrl":"10.1007/s10585-023-10236-4","url":null,"abstract":"Diagnosing malignant pleural effusions (MPE) is challenging when patients lack a history of cancer and cytopathology does not detect malignant cells in pleural effusions (PE). We investigated whether a systematic analysis of PE by flow cytometry immunophenotyping (FCI) had any impact on the diagnostic yield of MPE. Over 7 years, 570 samples from patients with clinical suspicion of MPE were submitted for the FCI study. To screen for epithelial malignancies, a 3-color FCI high sensitivity assay was used. The FCI results, qualified as \"malignant\" (FCI+) or \"non-malignant\" (FCI-), were compared to integrated definitive diagnosis established by clinicians based on all available information. MPE was finally diagnosed in 182 samples and FCI detected 141/182 (77.5%). Morphology further confirmed FCI findings by cytopathology detection of malignant cells in PE (n = 91) or histopathology (n = 29). Imaging tests and clinical history supported the diagnosis in the remaining samples. The median percentage of malignant cells was 6.5% for lymphoma and 0.23% for MPE secondary to epithelial cell malignancies. FCI identified a significantly lower percentage of EpCAM+ cells in cytopathology-negative MPE than in cytopathology-positive cases (0.02% vs. 1%; p < 0.0001). Interestingly, 29/52 MPE (55.8%) where FCI alerted of the presence of malignant cells were new diagnosis of cancer. Overall, FCI correctly diagnosed 456/522 samples (87.4%) suitable for comparison with cytopathology. These findings show that high sensitivity FCI significantly increases the diagnostic yield of MPE. Early detection of FCI + cases accelerates the diagnostic pathway of unsuspected MPE, thus supporting its implementation in clinical diagnostic work-up as a diagnostic tool.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CT-based deep learning model: a novel approach to the preoperative staging in patients with peritoneal metastasis. 基于CT的深度学习模型：腹膜转移患者术前分期的一种新方法。

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-01 Epub Date: 2023-10-05 DOI: 10.1007/s10585-023-10235-5

Jipeng Wang, Yuannan Hu, Hao Xiong, Tiantian Song, Shuyi Wang, Haibo Xu, Bin Xiong

{"title":"CT-based deep learning model: a novel approach to the preoperative staging in patients with peritoneal metastasis.","authors":"Jipeng Wang, Yuannan Hu, Hao Xiong, Tiantian Song, Shuyi Wang, Haibo Xu, Bin Xiong","doi":"10.1007/s10585-023-10235-5","DOIUrl":"10.1007/s10585-023-10235-5","url":null,"abstract":"Peritoneal metastasis (PM) is a frequent manifestation of advanced abdominal malignancies. Accurately assessing the extent of PM before surgery is essential for patients to receive optimal treatment. Therefore, we propose to construct a deep learning (DL) model based on enhanced computed tomography (CT) images to stage PM preoperatively in patients. All 168 patients with PM underwent contrast-enhanced abdominal CT before either open surgery or laparoscopic exploration, and peritoneal cancer index (PCI) was used to evaluate patients during the surgical procedure. DL features were extracted from portal venous-phase abdominal CT scans and subjected to feature selection using the Spearman correlation coefficient and LASSO. The performance of models for preoperative staging was assessed in the validation cohort and compared against models based on clinical and radiomics (Rad) signature. The DenseNet121-SVM model demonstrated strong patient discrimination in both the training and validation cohorts, achieving AUC was 0.996 in training and 0.951 validation cohort, which were both higher than those of the Clinic model and Rad model. Decision curve analysis (DCA) showed that patients could potentially benefit more from treatment using the DL-SVM model, and calibration curves demonstrated good agreement with actual outcomes. The DL model based on portal venous-phase abdominal CT accurately predicts the extent of PM in patients before surgery, which can help maximize the benefits of treatment and optimize the patient's treatment plan.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41108293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Congratulations to Prof. em. Garth L. Nicolson - co-founder of Clinical & Experimental Metastasis. 祝贺临床与实验转移瘤联合创始人Garth L.Nicolson教授。

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-01 Epub Date: 2023-10-21 DOI: 10.1007/s10585-023-10239-1

Jörg Haier, Jonathan Sleeman

引用次数: 0

Development and adaptations of the Graded Prognostic Assessment (GPA) scale: a systematic review. 分级预后评估（GPA）量表的发展和适应：一项系统综述。

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-01 Epub Date: 2023-10-11 DOI: 10.1007/s10585-023-10237-3

Luana Marques Ribeiro, Fernanda Ferreira Bomtempo, Rebeka Bustamante Rocha, João Paulo Mota Telles, Eliseu Becco Neto, Eberval Gadelha Figueiredo

{"title":"Development and adaptations of the Graded Prognostic Assessment (GPA) scale: a systematic review.","authors":"Luana Marques Ribeiro, Fernanda Ferreira Bomtempo, Rebeka Bustamante Rocha, João Paulo Mota Telles, Eliseu Becco Neto, Eberval Gadelha Figueiredo","doi":"10.1007/s10585-023-10237-3","DOIUrl":"10.1007/s10585-023-10237-3","url":null,"abstract":"The Graded Prognostic Assessment (GPA) score has the best accuracy among prognostic scales for patients with brain metastases (BM). A wide range of GPA-derived scales have been established to different types of primary tumor BM. However, there is a high variability between them, and their characteristics have not been described altogether yet. We aim to summarize the features of the existent GPA-derived scales and to compare their predictor factors and their uses in clinical setting. Medline was searched from inception until January 2023 to identify studies related to the development, update, or validation of GPA. The initial search yielded 1,083 results. 16 original studies and 16 validation studies were included, comprising a total of 33,348 patients. 13 different scales were assessed, including: GPA, Diagnosis-Specific GPA, Extracranial Score, Lung-molGPA, Updated Renal GPA, Updated Gastrointestinal GPA, Modified Breast GPA, Integrated Melanoma GPA, Melanoma Mol GPA, Sarcoma GPA, Hepatocellular Carcinoma GPA, Colorectal Cancer GPA, and Uterine Cancer GPA. The most prevalent prognostic predictors were age, Karnofsky Performance Status, number of BM, and presence or absence of extracranial metastases. Treatment modalities consisted of whole brain radiation therapy, stereotactic radiosurgery, surgery, cranial radiotherapy, gamma knife radiosurgery, and BRAF inhibitor therapy. Median survival rates with no treatment and with a specific treatment ranged from 6.1 weeks to 33 months and from 3.1 to 21 months, respectively. Original GPA and GPA-derived scales are valid prognostic tools, but with heterogeneous survival results when compared to each other. More studies are needed to improve scientific evidence of these scales.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41193271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on ¹⁸F-FDG. PET/CT在评估结直肠癌肝转移中的应用：以18F-FDG为重点的综述。

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-12-01 Epub Date: 2023-09-08 DOI: 10.1007/s10585-023-10231-9

Mahdi Zirakchian Zadeh

{"title":"PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on 18F-FDG.","authors":"Mahdi Zirakchian Zadeh","doi":"10.1007/s10585-023-10231-9","DOIUrl":"10.1007/s10585-023-10231-9","url":null,"abstract":"Approximately 25% of those who are diagnosed with colorectal cancer will develop colorectal liver metastases (CRLM) as their illness advances. Despite major improvements in both diagnostic and treatment methods, the prognosis for patients with CRLM is still poor, with low survival rates. Accurate employment of imaging methods is critical in identifying the most effective treatment approach for CRLM. Different imaging modalities are used to evaluate CRLM, including positron emission tomography (PET)/computed tomography (CT). Among the PET radiotracers, fluoro-18-deoxyglucose (18F-FDG), a glucose analog, is commonly used as the primary radiotracer in assessment of CRLM. As the importance of 18F-FDG-PET/CT continues to grow in assessment of CRLM, developing a comprehensive understanding of this subject becomes imperative for healthcare professionals from diverse disciplines. The primary aim of this article is to offer a simplified and comprehensive explanation of PET/CT in the evaluation of CRLM, with a deliberate effort to minimize the use of technical nuclear medicine terminology. This approach intends to provide various healthcare professionals and researchers with a thorough understanding of the subject matter.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10183064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Travelling under pressure - hypoxia and shear stress in the metastatic journey. 在压力下旅行——转移过程中的缺氧和剪切应力。

IF 4 3区医学

Clinical & Experimental Metastasis Pub Date : 2023-10-01 Epub Date: 2023-07-25 DOI: 10.1007/s10585-023-10224-8

Ece Su Ildiz, Ana Gvozdenovic, Werner J Kovacs, Nicola Aceto

引用次数: 1